The role of glutamate in the pathophysiology of Parkinson's disease

Funct Neurol. 1996 Jan-Feb;11(1):3-15.
No abstract available

Publication types

  • Review

MeSH terms

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / adverse effects
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / pharmacology
  • Animals
  • Antiparkinson Agents / pharmacology
  • Antiparkinson Agents / therapeutic use
  • Basal Ganglia / anatomy & histology
  • Basal Ganglia / physiology
  • Basal Ganglia / physiopathology
  • Disease Models, Animal
  • Dopamine / physiology
  • Excitatory Amino Acid Antagonists / pharmacology
  • Excitatory Amino Acid Antagonists / therapeutic use
  • Glutamic Acid* / physiology
  • Glutamic Acid* / toxicity
  • Humans
  • Ion Channel Gating / physiology
  • Mitochondria / drug effects
  • Mitochondria / physiology
  • Neural Pathways / anatomy & histology
  • Neural Pathways / physiology
  • Neural Pathways / physiopathology
  • Neuroprotective Agents / pharmacology
  • Neuroprotective Agents / therapeutic use
  • Parkinson Disease / drug therapy
  • Parkinson Disease / physiopathology*
  • Primates
  • Rats
  • Receptors, AMPA / physiology
  • Receptors, Glutamate / classification
  • Receptors, Glutamate / physiology
  • Receptors, N-Methyl-D-Aspartate / physiology*

Substances

  • Antiparkinson Agents
  • Excitatory Amino Acid Antagonists
  • Neuroprotective Agents
  • Receptors, AMPA
  • Receptors, Glutamate
  • Receptors, N-Methyl-D-Aspartate
  • Glutamic Acid
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Dopamine